至正股份(603991.SH)終止公司重大資產出售事項
格隆匯12月23日丨至正股份(603991.SH)公佈,2020年12月23日,公司召開第三屆董事會第六次會議和第三屆監事會第五次會議,審議通過了《關於終止公司重大資產出售暨關聯交易事項的議案》等相關議案。本次重大資產出售事項自啟動以來,公司組織相關各方積極推進相關工作,與交易對方、中介機構就本次重大資產出售事項進行了反覆探討和溝通,但由於公司及交易對方面臨的外部環境發生一定的變化,經公司與交易對方多次協商談判,各方一致認為在當前的證券市場和行業環境下不適宜繼續推動本次重大資產出售。為維護公司及全體股東尤其是中小股東的利益,經交易雙方審慎研究並友好協商,一致決定終止本次重大資產出售事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.